Recent findings revealed that type 2 diabetes mellitus (T2D) is a chronic
inflammatory disease and an islet amyloid polypeptide (IAPP)/amylin, is
deposited within pancreatic islets. IAPP/amylin has been reported to activate
NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome in
infiltrated macrophages. NLRP3, an intracellular pattern recognition receptor,
has been shown to recognize pathogens and/or metabolites and complexes with the
adopter protein apoptosis-associated speck-like protein containing a
caspase-recruitment domain ASC to form a huge complex, called an inflammasome,
an interleukin (IL)-1β-processing platform. Although reactive oxygen species
(ROS) were reported to be involved in activation of NLRP3 inflammasome, we were
hypothesized that IAPP could directly activate NLRP3 inflammasome, leading to
islets β-cell death. We analyzed expression of the inflammasome components ASC,
NLRP3, caspase-1, IL-1β, IAPP/amylin, and insulin immunohistochemically in
Langerhans’ islets of autopsy cases. The initial event of NLRP3 inflammasome
activation was assessed using a cell-free system consisting of NLRP3 and ASC
with the amplified luminescent proximity homogeneous assay. IAPP/amylin
deposition in Langerhans’ islets was detected and significantly correlated with
expressions of IL-1β and ASC. IAPP/amylin directly interacted with NLRP3 and
initiated an interaction between NLRP3 and ASC in a cell-free system. The
deposition of IAPP/amylin in β-cells of Langerhans’ islets may act together with
the expression level of an inflammasome component, ASC, to regulate IL-1β
processing, and directly lead to the dysfunction of β-cells. The interaction
between IAPP/amylin and NLRP3 could be an attractive drug target to avoid both
inflammation and β-cell death for T2D therapy.